Welcome to Heart Matters – Empowering Heart Health
Breaking News

Could Drug-Coated Balloons Replace Permanent Heart Stents?

For decades, heart stents have been the mainstay treatment for coronary artery disease (CAD), restoring blood flow in narrowed or blocked arteries. While drug-eluting stents (DES) have significantly improved outcomes, they come with long-term considerations, including the need for dual antiplatelet therapy (DAPT) and the risk of in-stent restenosis or stent thrombosis.

Recently, drug-coated balloons (DCBs) have emerged as an alternative, particularly in specific cases such as in-stent restenosis and small vessel disease. But could DCBs one day replace permanent stents altogether? Let’s explore the potential of this evolving technology.

 

What Are Drug-Coated Balloons?

DCBs are specialized angioplasty balloons coated with anti-proliferative drugs, such as paclitaxel or sirolimus, which are designed to reduce excessive tissue growth inside arteries. Unlike stents, which are permanently implanted, DCBs deliver medication to the artery wall during balloon inflation and are then removed, leaving no permanent metal structure behind.

 

How Do Drug-Coated Balloons Work?

The DCB procedure is similar to traditional balloon angioplasty, where a balloon is inflated at the site of a blockage to restore blood flow. The key difference is that as the balloon expands, it delivers medication directly to the arterial wall, helping to prevent re-narrowing (restenosis).

DCBs have shown strong clinical success in:

  • Treating in-stent restenosis (when a previously placed stent re-narrows due to tissue overgrowth)
  • Small vessel disease, where placing a stent may be technically difficult
  • Side branch lesions in bifurcation disease, reducing the need for two-stent strategies

 

Could Drug-Coated Balloons Replace Stents?

DCBs offer several potential advantages over stents:

  • No permanent metal implant, preserving natural artery flexibility
  • Lower risk of late complications, such as late stent thrombosis or restenosis
  • Reduced need for prolonged dual antiplatelet therapy, lowering the risk of bleeding complications
  • Fewer challenges for future interventions, as there is no stent to navigate around in case additional procedures are needed

However, DCBs also have limitations that currently prevent them from fully replacing stents:

  • They do not provide mechanical support, which is crucial in larger or heavily calcified arteries
  • Recoil and dissection risks, meaning some arteries may collapse or develop tears without a stent to scaffold them
  • Limited long-term data compared to drug-eluting stents, which have decades of research backing their use

 

The Future of DCBs in Coronary Artery Disease

While DCBs are unlikely to completely replace stents in the near future, their role in select cases is expanding. Emerging research suggests that in certain patient groups, particularly those with small vessel disease, bifurcations, or specific lesion types, DCBs may provide outcomes comparable to or better than stents.

Newer sirolimus-coated balloons and advances in balloon delivery technology may further improve DCB efficacy, opening the door for broader applications in coronary interventions.

Conclusion

Drug-coated balloons represent an exciting innovation in interventional cardiology, offering a stent-free approach in select cases. While stents remain the gold standard for treating most significant coronary blockages, DCBs are carving out a niche and may play a larger role in future treatment strategies.

For now, the best approach depends on individual patient needs, lesion characteristics, and ongoing technological advances. Permanet heart stents are the primary way to manage narrowings for now but no doubt there will be increasing application of drug coated balloons to more and more lesions and for more patients as ongoing trial results are released. If you are considering coronary intervention, speak with your cardiologist to determine the most suitable treatment option for your specific condition.

About the author

Heart Matters, edited by cardiologist Professor Peter Barlis, is a trusted resource that offers clear and accurate information on cardiovascular health. It bridges the gap between scientific research and everyday understanding, empowering you to make informed choices and take an active role in supporting your heart health.

Our Youtube Channel

Discover our Heart Matters YouTube channel, where we bring heart health to life. From explaining common conditions and symptoms to discussing the latest research, our engaging videos simplify complex topics, ensuring you have access to valuable knowledge for a healthier heart. Subscribe now and embark on a journey of education, empowerment, and inspiration.

Editor's Picks

Subscribe to our newsletter and be the first to receive valuable insights, tips, and resources on heart health.

other anti-anginals

When first-line therapies for angina, such as beta blockers, calcium channel blockers, and nitrates, prove inadequate or are not well-tolerated, second-line therapies may be considered.
Perhexiline is a unique medication that enhances the heart's ability to utilize fatty acids for energy, reducing its reliance on oxygen and lowering oxygen demand. This action helps improve blood flow and alleviates chest pain in some patients with refractory angina.
Nicorandil is another second-line option with a dual mechanism of action. It opens potassium channels in smooth muscle cells, causing vasodilation and enhancing coronary blood flow. Additionally, nicorandil also stimulates nitric oxide release, further dilating blood vessels and reducing heart workload.
Trimetazidine is an anti-ischemic agent that improves cardiac efficiency by enhancing glucose metabolism and shifting the heart's energy production to a more oxygen-efficient process. As second-line therapies, these medications offer alternative approaches for managing angina in individuals who do not respond adequately to first-line treatments or those experiencing side effects from other medications.

lipid lowering therapies

Lipid-lowering therapies are essential in managing coronary artery disease (CAD), a condition where the arteries supplying blood to the heart become narrowed. Among the most commonly prescribed treatments are statins, which reduce cholesterol production in the liver and significantly lower the risk of heart attacks and strokes.

Other medications may be used to target different aspects of lipid metabolism:

  • Ezetimibe helps reduce the absorption of cholesterol in the gut
  • Fibrates lower triglyceride levels
  • Niacin can help raise high-density lipoprotein (HDL) cholesterol

In recent years, a newer class of medications known as PCSK9 inhibitors—such as Repatha (evolocumab)—has become available. These drugs block a specific enzyme involved in cholesterol regulation and can dramatically lower LDL cholesterol, particularly in patients who do not achieve target levels with statins alone.

Together, these therapies provide a range of options to personalise treatment and improve cardiovascular outcomes.

Nitrates

Nitrates for Angina Relief

Nitrates are widely used to treat angina and provide quick relief from chest pain. These medications are commonly available as sublingual sprays or tablets, skin patches, and long-acting tablets.

Nitrates work by dilating blood vessels, allowing for increased blood flow and reduced vascular resistance. This reduces the heart’s workload and lowers its oxygen demand, offering prompt relief from angina symptoms.

Sublingual nitrates act quickly and are typically used at the onset of angina symptoms, while patches and long-acting tablets are used for ongoing prevention.

Common side effects include headaches, dizziness, and flushing. These often improve with continued use but should be discussed with a healthcare provider if persistent or bothersome.

calcium channel blockers

Calcium channel blockers, including amlodipine, felodipine, Cardizem (diltiazem), and verapamil, are commonly prescribed for the treatment of angina.

These medications work by inhibiting the influx of calcium into the muscle cells of the heart and blood vessels, causing them to relax. This relaxation leads to the widening of blood vessels, which improves blood flow and reduces blood pressure.

For individuals with angina, calcium channel blockers reduce the heart’s workload and oxygen demand, helping to relieve chest pain and prevent angina episodes.

While effective, they may cause side effects such as headaches, dizziness, facial flushing, and ankle swelling. These effects should be monitored and discussed with your healthcare provider if they persist.

Beta blockers

Beta blockers, such as metoprolol, propranolol, atenolol, carvedilol, and bisoprolol, play a crucial role in managing angina.

These medications work by blocking specific receptors in the heart, which slows the heart rate and reduces the strength of each contraction. This results in a lower oxygen demand by the heart and helps relieve chest pain associated with angina.

Beta blockers are highly effective in both relieving symptoms and preventing angina episodes. However, they may cause side effects in some individuals, including tiredness, worsened asthma symptoms, more vivid dreams, and erectile dysfunction in some males.

It is important to consult your healthcare provider to determine whether beta blockers are a suitable option for your angina and overall heart health.

Anti-platelet Medications

Anti-platelet medications play a crucial role in preventing blood clot formation and reducing the risk of serious cardiovascular events such as heart attacks and strokes. Commonly used agents include aspirin, clopidogrel, and ticagrelor.

 

Aspirin: This well-known medication inhibits platelet activation, reducing the likelihood that platelets will clump together and form clots. It is widely used for both primary and secondary prevention of heart attacks and strokes.

 

Clopidogrel: A potent anti-platelet agent, clopidogrel works by blocking specific receptors on platelets to prevent aggregation. It is commonly prescribed for patients with acute coronary syndrome, those undergoing stent placement, and some individuals with peripheral arterial disease.

 

Ticagrelor: Ticagrelor also inhibits platelet activation and is typically used in the treatment of acute coronary syndrome. It is often prescribed alongside aspirin to provide dual anti-platelet therapy and further reduce the risk of heart-related events.